With healthcare systems across Europe stretched to breaking point, the challenges for biopharma companies are that they must go beyond articulating a medicine’s clinical and cost arguments and work actively with payers to demonstrate its full value.

Challenging times can also bring opportunities, as in the UK, where a new era of partnerships is offering Biopharma the chance to redefine its relationship with the National Health Service (NHS). In the build-up to the launch of the UK Clinical Commissioning Groups in 2013, a number of trends are emerging from inside the local NHS, many of which present market access challenges for Biopharma.